This article is more than 5 years old. Information may no longer be current.
Nicox revenues total €7 million through first 9 months of year
Nicox reported €7 million in revenues in the first 9 months of this year compared with €3.2 million in the same period of 2014, according to a press release.
“The first 9 months of 2015 were marked by the continuous growth of our European commercial operations, which increased by 119% over the same period of 2014, and as well as by the new drug application acceptance for filing of Vesneo, our leading nitric oxide-donating candidate partnered with Valeant in glaucoma,” Michele Garufi, CEO and chairman of Nicox, said in the release.
The FDA has set an action date of July 21, 2016, to complete its review for Vesneo (latanoprostene bunod ophthalmic solution 0.024%).
Through Sept. 30, cash, cash equivalents and financial instruments were reported at €34.5 million.